deleobuvir: Clinical Trials

2 trials of deleobuvir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow deleobuvir: new trials by email Literature Review of deleobuvir trials Research Report on deleobuvir

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3
Ribavirin, BI 207127 high dose, Faldaprevir - Hepatitis C, Chronic
Phase 2CompletedBoehringer Ingelheim352013-04-012015-11-20
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
BI 207127, BI 201335, Ribavirin - Hepatitis C, Chronic
Phase 2CompletedBoehringer Ingelheim4882010-05-012016-02-01

Conditions studied

Hepatitis C, Chronic (2)

Sponsors

Boehringer Ingelheim (2)

Countries

Germany (2)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Austria (1)  ·  France (1)  ·  New Zealand (1)  ·  Portugal (1)  ·  Romania (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Results publications

PMID 23558093, PMID 23944300, PMID 25512403, PMID 26650626, PMID 27140229, PMID 28030579

NIH funding

2009 (1)